Publication Name	World Journal of Hypertension
Manuscript ID	14315
Country	China

Received	2014-09-29 11:37
Peer-Review Started	2014-09-29 21:45
To Make the First Decision	2015-01-20 13:31
Return for Revision	2015-01-30 17:17
Revised	2015-03-10 10:42
Second Decision	2015-04-10 18:08
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-04-20 14:31
Articles in Press	2015-04-20 14:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-05 12:43
Publish the Manuscript Online	2015-05-21 14:33

ISSN	2220-3168 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Review
Article Title	Progress in neuregulin/ErbB signaling and chronic heart failure
Manuscript Source	Invited Manuscript
All Author List	Hong-Kun Yin, Xin-Yan Li, Zheng-Gang Jiang and Ming-Dong Zhou
Funding Agency and Grant Number
Corresponding Author	Ming-Dong Zhou, PhD, Zensun (Shanghai) Sci and Tech Co., Ltd., Zhangjiang Hi-tech Park, No. 68 Ju Li Road, Shanghai 201203, China. mdzhou@zensun.com
Key Words	ErbB; Epigenetic modification; Heart failure; Metabolism; Neuregulin-1
Core Tip	Neuregulin (NRG)-1/ErbB signaling plays a critical role in the development of the heart and the maintenance of cardiac function. In both pre-clinical and clinical studies, NRG-1 has demonstrated efficacy as a therapeutic agent for the treatment of heart failure. In model animals and clinical trials, short-term treatment with recombinant NRG-1 protein results in a long-term beneficial effect. Here, the mechanisms underlying the therapeutic effects of NRG-1 during heart failure are reviewed. The results indicate that NRG-1 induces a cardiac reverse remodeling process through the initiation of changes in both cell metabolism and epigenetic modification.
Publish Date	2015-05-21 14:33
Citation	Yin HK, Li XY, Jiang ZG, Zhou MD. Progress in neuregulin/ErbB signaling and chronic heart failure. World J Hypertens 2015; 5(2): 63-73
URL	http://www.wjgnet.com/2220-3168/full/v5/i2/63.htm
DOI	http://dx.doi.org/10.5494/wjh.v5.i2.63

Full Article (PDF)	WJH-5-63.pdf
Full Article (Word)	WJH-5-63.doc
Manuscript File	14315-Review.docx
Answering Reviewers	14315-Answering reviewers.pdf
Audio Core Tip	14315-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	14315-Conflict-of-interest statement.pdf
Copyright License Agreement	14315-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	14315-Language certificate.pdf
Peer-review Report	14315-Peer-review(s).pdf
Scientific Misconduct Check	14315-Scientific misconduct check.pdf
Scientific Editor Work List	14315-Scientific editor work list.pdf